Waldenstrom Macroglobulinemia clinical trials at UCSF

1 research study open to eligible people

Waldenstrom macroglobulinemia is a rare blood cancer that makes too much antibody. UCSF is part of a study giving a new drug to adults with B-cell cancers that returned after treatment. The study gathers facts on safety and anti-cancer effects.

Showing trials for

  • NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

    open to eligible people ages 18 years and up

    This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

    San Francisco, California and other locations

Our lead scientists for Waldenstrom Macroglobulinemia research studies include .

Last updated: